Phase 3 Data Support ADUHELM™ Ability to Reduce Alzheimer’s Disease Clinical Decline
New Phase 3 Data has shown a positive correlation between the human monoclonal antibody ADUHELM™ treatment effect on biomarkers and
Read moreNew Phase 3 Data has shown a positive correlation between the human monoclonal antibody ADUHELM™ treatment effect on biomarkers and
Read moreGenentech’s investigational antibody for the treatment of early-stage Alzheimer’s disease, Gantenerumab, has been granted Breakthrough Therapy Designation by the U.S.
Read moreTezepelumab, developed by AstraZeneca in collaboration with Amgen, has been granted Orphan Drug Designation (ODD) in the US FDA for
Read moreMerck (NYSE: MRK), known as MSD outside the United States and Canada, announced on Saturday the first results from the
Read moreCalypso Biotech, a leading biotechnology company in the development of Interleukin-15 (IL-15) targeted therapies, announces today completion of the dosing
Read moreThe UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) has granted a Conditional Marketing Authorization (CMA) for Regeneron’s antibody cocktail to treat
Read moreA UK-based consortium consisting of BiologIC Technologies, Biopharm Services, CPI, Pall Corporation, and SCIEX has announced the start of a
Read moreHistoSure’s novel monoclonal COVID-19 antibodies developed to enable tissue-based detection of viral infection in human clinical samples have shown excellent
Read moreThe range of clinical responses to SARS-CoV-2 infection is extremely broad, a factor making the disease particularly difficult to properly
Read moreGSK and Vir Biotechnology announced that the monoclonal antibody sotrovimab (VIR-7831) has received Emergency Use Authorization (EUA) from the US
Read more